Multi-antigen Specific CD8+ T Cells
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Multi-antigen Specific CD8+ T Cells, covering 2025-05-25 to 2025-05-25. Get the full timeline:
Most recent: Clinical Trial Update: Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor [Phase 1]